Idera Pharmaceuticals Announces Appointment of Carol A. Schafer to its Board of Directors
December 18 2018 - 4:05PM
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that
Carol A. Schafer joined its Board of Directors, effective December
18, 2018.
Ms. Schafer is a seasoned financial professional with more than
25 years of experience in investment banking and equity capital
markets, as well as corporate finance and business development in
the biopharmaceutical sector. Ms. Schafer most recently
served as Vice Chair, Equity Capital Markets at Wells Fargo
Securities. Prior to Wells Fargo, Ms. Schafer served as Vice
President of Finance and Business Development at Lexicon
Pharmaceuticals. Earlier in her career, Ms. Schafer served as
an Equity Capital Markets Sector Head in her role as a Managing
Director at J.P. Morgan. Ms. Schafer received a B.A. from
Boston College and an M.B.A from New York University.
“Carol brings a unique set of skills and experience that
traverses the financial and corporate biotech landscape and will be
incredibly valuable to our board as we continue to advance Idera’s
mission to bring forward options for patients suffering from
life-threatening diseases and ultimately create long-term
shareholder value,” stated James Geraghty, Chairman of Idera’s
Board of Directors.
Ms. Schafer will be succeeding Mr. William Reardon, who will be
resigning from the Board effective March 10, 2019.
“We are extremely thankful for the contributions provided by
Bill through his 16 years of service on the Board of Idera,”
continued Mr. Geraghty. “We also appreciate Bill’s further
dedication to remain in the role to enable continuity and assist
the transition of the Audit Committee Chairperson role to Carol
through the 2018 year-end financial filing period.”
About Idera PharmaceuticalsHarnessing the
approach of the earliest researchers in immunotherapy and the
Company’s vast experience in developing proprietary immunology
platforms, Idera’s lead development program is focused on priming
the immune system to play a more powerful role in fighting cancer,
ultimately increasing the number of people who can benefit from
immunotherapy. Idera also continues to focus on the acquisition,
development and ultimate commercialization of drug candidates for
both oncology and rare disease indications characterized by small,
well-defined patient populations with serious unmet needs. To learn
more about Idera, visit www.iderapharma.com.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
All statements, other than statements of historical fact, included
or incorporated in this press release, including statements
regarding the Company’s strategy, future operations,
collaborations, cash resources, financial position, future
revenues, projected costs, prospects, clinical trials, plans and
objectives of management, are forward-looking statements. The words
“believes,” “anticipates,” “estimates,” “plans,” “expects,”
“intends,” “may,” “could,” “should,” “potential,” “likely,”
“projects,” “continue,” “will,” and “would” and similar expressions
are intended to identify forward-looking statements, although not
all forward-looking statements contain these identifying words.
Idera cannot guarantee that it will actually achieve the plans,
intentions or expectations disclosed in its forward-looking
statements and you should not place undue reliance on the Company’s
forward-looking statements. There are a number of important factors
that could cause Idera’s actual results to differ materially from
those indicated or implied by its forward-looking statements,
including whether the Company’s cash resources will be sufficient
to fund the Company’s continuing operations and the further
development of the Company’s programs for the period anticipated;
whether interim results from a clinical trial will be predictive of
the final results of the trial; whether results obtained in
preclinical studies and clinical trials will be indicative of the
results that will be generated in future clinical trials; whether
products based on the Company’s technology will advance into or
through the clinical trial process when anticipated or at all or
warrant submission for regulatory approval; whether such products
will receive approval from the U.S. Food and Drug Administration or
equivalent foreign regulatory agencies; whether, if the Company's
products receive approval, they will be successfully distributed
and marketed; whether the Company's collaborations will be
successful; and such other important factors set forth under the
caption “Risk Factors” in the Company’s Annual Report on Form 10-K
for the period ended December 31, 2017 and in the Company’s
Quarterly Report on Form 10-Q for the period ended September 30,
2018. Although Idera may elect to do so at some point in the
future, the Company does not assume any obligation to update any
forward-looking statements and it disclaims any intention or
obligation to update or revise any forward-looking statement,
whether as a result of new information, future events or
otherwise.
Investor and Media ContactRobert DoodyVice
President, Investor Relations and Corporate CommunicationsOffice:
484-348-1677rdoody@iderapharma.com
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From May 2024 to Jun 2024
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Jun 2023 to Jun 2024